secwatch.observer — SEC 8-K summary
======================================

Issuer:     Icosavax, Inc. (—)
CIK:        0001786255
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001104659-24-025251
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Icosavax completes acquisition by AstraZeneca; shareholders receive $15 + CVR up to $5
--------------------------------------------------------------------------------

- Acquisition closed: Icosavax shareholders receive $15.00 per share cash plus one CVR (up to $5.00 per share).
- Tender offer resulted in ~70.7% of shares validly tendered; all conditions satisfied.
- Shares to be delisted from Nasdaq; trading suspended prior to open on Feb 20, 2024.
- Board of directors replaced; Icosavax now wholly owned subsidiary of AstraZeneca.
- All outstanding equity awards converted to cash and CVRs per Merger Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786255/000110465924025251/0001104659-24-025251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786255/000110465924025251/tm246604d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-025251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer